Standard Biotools (LAB) EBT (2010 - 2026)

Standard Biotools (LAB) has 17 years of EBT data on file, last reported at -$14.6 million in Q1 2026.

• EBT for Q1 2026 came in at -$14.6 million, up 37.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.3 million (up 38.64% YoY), and the FY2025 annual result was -$28.2 million, down 16.16% from the prior year.
• EBT slipped to -$14.6 million in Q1 2026 per LAB's latest filing, from $46.5 million in the prior quarter.
• Over five years, EBT peaked at $46.5 million in Q4 2025 and troughed at -$76.9 million in Q1 2022.
• A 5-year average of -$17.1 million and a median of -$20.9 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2023: EBT sank 275.08% in 2022, then soared 1193.7% in 2023.
• A 5-year view of EBT shows it stood at -$1.9 million in 2022, then soared by 1193.7% to $20.6 million in 2023, then soared by 90.06% to $39.2 million in 2024, then advanced by 18.49% to $46.5 million in 2025, then tumbled by 131.43% to -$14.6 million in 2026.
• Business Quant data shows LAB's EBT at -$14.6 million in Q1 2026, $46.5 million in Q4 2025, and -$32.9 million in Q3 2025.